Back HIV/AIDS

HIV / AIDS

AIDS 2016: SEARCH Study Exceeds 90-90-90 Targets After 2 Years of HIV Test-and-Treat

A large study that embeds "'test-and-treat" for HIV within a larger multi-disease prevention campaign in rural Kenya and Uganda has achieved 82% viral suppression after 2 years, and has already exceeded UNAIDS targets for viral suppression after 1 year of activity, investigators from the SEARCH study reported at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

AIDS 2016: South Africa Has Driven Mother-to-Child HIV Transmission Down to 4%

Mother-to-child transmission (MTCT) of HIV at a population level was just over 4% at 18 months of follow-up in a national evaluation in South Africa, Ameena Goga, presenting on behalf of the South African prevention of mother-to-child transmission Evaluation Group, told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban. 

alt

AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy

A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference (AIDS 2016) this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.

alt

AIDS 2016: HIV Treatment Programs Need to Prepare for a "Youth Bulge"

Treatment programs in sub-Saharan Africa must prepare for a growing population of adolescents over the next few years as children born with HIV grow up and begin a transition from child health services to adult clinics, Mhairi Maskew from the University of Witwatersrand told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

AIDS 2016: Young Gay Men Can Do Well on PrEP, But May Need More Support

Young gay and bisexual men had good adherence to Truvada for pre-exposure prophylaxis (PrEP) during the first few months of a demonstration project with close monitoring, but adherence slipped once follow-up switched from monthly to quarterly, suggesting that young people using PrEP may require more on-going support, according to a presentation at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

AIDS 2016: Australia Adopts Ambitious Plan to Use PrEP to "Virtually Eliminate" HIV

Australia plans an ambitious program of pre-exposure prophylaxis (PrEP) provision for gay men at high risk of HIV, with the aim of "virtually eliminating" HIV in the gay community by 2020, Iryna Zablotska from the University of New South Wales told delegates at the 21st International AIDS Conference (AIDS 2016) this week in Durban. PrEP roll-out is also underway in some countries in Kenya and South Africa.

alt

AIDS 2016: PrEP Can Further Reduce HIV Risk After Partner Starts Antiretroviral Treatment

Offering Truvada pre-exposure prophylaxis (PrEP) to the HIV-negative partner in a serodiscordant couple during the first 6 months after the HIV-positive partner starts antiretroviral therapy (ART) can serve as a "bridge" to further reduce the likelihood of HIV infection, researchers reported at the 21st International AIDS Conference (AIDS 2016) taking place this week in Durban, South Africa.

alt